BEI Medical
This article was originally published in The Gray Sheet
Executive Summary
Sells its GyneSys and HysteroSys infertility catheter product lines to Johnson & Johnson's Ethicon division for $975,000 plus deferred payments based on future product sales. Under terms of the deal, BEI will supply the products to Ethicon on a non-exclusive basis for up to a year. The move reflects BEI's concentration on core products in women's health and a focus on developing its Hydro ThermAblator system, which is currently in clinical trials, for treatment of excessive uterine bleeding, the company says